Imbria Pharmaceuticals Announces Publication of IMPROVE-DiCE Phase 2a Data in Circulation, Demonstrating Ninerafaxstat as a Potential First-in-Class Therapy Targeting Cardiac ...

Data provide first human validation of cardiac energetics modulation as a therapeutic target in cardiometabolic heart disease, including heart failure with preserved ejection fraction (HFpEF) In ...
The Caledonian-Record

Imbria Pharmaceuticals Announces Publication of IMPROVE-DiCE Phase 2a Data in Circulation,

Data provide first human validation of cardiac energetics modulation as a therapeutic target in cardiometabolic heart disease, including heart failure with preserved ejection fraction (HFpEF) ...
Nature

Statins improve cardiac endothelial function to prevent heart failure with preserved ejection fraction through upregulating circRNA-RBCK1

The Nature Index 2024 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
Opinion
HealioOpinion

Challenge the ‘status quo’ of serial prescription of proven HFpEF therapies

Simultaneous or rapid initiation of evidence-based therapies significantly improves quality of life and outcomes in patients with heart failure with moderately reduced or preserved ejection fraction, ...
Medscape

Pharmacologic Management of Heart Failure with Preserved Ejection Fraction

The role of ACE inhibitors in the management of HFPEF is less significant compared with their role in the management of heart failure with left ventricular systolic dysfunction. For patients with ...
Medical Dialogues

High-Sensitivity CRP Identified as a Powerful Prognostic Marker in Heart Failure with Reduced Ejection Fraction: AHJ, December 2025

According to a recent study, in heart failure with reduced ejection fraction (HFrEF) patients, elevated high-sensitivity ...